Andersson M, Lindqvist N, Svensson C, Ek L, Pipkorn U
ENT-Dept, University Hospital, Lund, Sweden.
Clin Otolaryngol Allied Sci. 1993 Feb;18(1):30-3. doi: 10.1111/j.1365-2273.1993.tb00805.x.
Topical steroids are known to be effective in allergic inflammatory airway diseases. However, progress in the treatment of these diseases has also called for the use of unadulterated drugs, without lubricants and preservatives. Rhinocort Turbuhaler, a multi-dose inhaler containing budesonide as a pure powder, is a newly developed device without any carrier gas, preservatives or lubricants. The efficacy and tolerance of this product were evaluated in 60 patients with birch pollen rhinitis. After a run-in period of 1 week the patients received once daily for 4 weeks either budesonide pure powder (400 micrograms) or placebo in a double-blind randomized fashion. Assessment of efficacy was made by comparing scores for different nasal and eye symptoms. The additional use of antihistamine tablets was assessed. In 22 of the patients nasal peak inspiratory flow rate was measured before and after 1 week of treatment. Budesonide was significantly more effective than placebo in controlling the nasal symptoms (P-values ranging from 0.011-0.045). The use of antihistamine tablets was significantly lower in the budesonide group (P = 0.012). The nasal inspiratory flow rate was increased after 1 week of treatment in the budesonide treated group of patients as compared with placebo (P = 0.007). No differences were observed between the groups with regard to eye symptoms or adverse effects. The results show that budesonide delivered from a dry powder inhaler is an effective and well tolerated treatment of seasonal allergic rhinitis.
局部用类固醇在过敏性炎症性气道疾病中被认为是有效的。然而，这些疾病治疗方面的进展也要求使用纯净药物，不含润滑剂和防腐剂。Rhinocort Turbuhaler是一种多剂量吸入器，含有作为纯粉末的布地奈德，是一种新开发的不含任何载气、防腐剂或润滑剂的装置。在60例桦树花粉性鼻炎患者中评估了该产品的疗效和耐受性。经过1周的导入期后，患者以双盲随机方式每日接受一次布地奈德纯粉末（400微克）或安慰剂，持续4周。通过比较不同鼻部和眼部症状的评分来评估疗效。评估了抗组胺药片剂的额外使用情况。在22例患者中，在治疗1周前后测量了鼻吸气峰流速。布地奈德在控制鼻部症状方面明显比安慰剂更有效（P值范围为0.011 - 0.045）。布地奈德组抗组胺药片剂的使用明显更低（P = 0.012）。与安慰剂相比，布地奈德治疗组患者在治疗1周后鼻吸气流速增加（P = 0.007）。在眼部症状或不良反应方面，两组之间未观察到差异。结果表明，干粉吸入器递送的布地奈德是季节性过敏性鼻炎的一种有效且耐受性良好的治疗方法。
